IMUX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
35.3M
+6.3%
33.2M
+42.5%
23.3M
-10.3%
26.0M
-4.0%
27.1M
R&D
25.9M
+1.2%
25.6M
+34.4%
19.1M
-4.7%
20.0M
-6.4%
21.4M
SG&A
9.4M
+23.5%
7.6M
+78.7%
4.3M
-28.8%
6.0M
+4.7%
5.7M
Operating Income
-35327000
-6.3%
-33235000
-42.5%
-23327000
+10.3%
-25993000
+4.0%
-27083000
EBITDA
-35293000
-6.3%
-33202000
-42.6%
-23285000
+10.3%
-25953000
+4.0%
-27040000
Net Income
-34099000
-4.6%
-32588000
-68.8%
-19300000
+24.5%
-25579000
+4.6%
-26820000
EPS (Basic)
$-0.80
+25.9%
$-1.08
-125.0%
$-0.48
+63.1%
$-1.30
+36.0%
$-2.03
EPS (Diluted)
$-0.80
+25.9%
$-1.08
-125.0%
$-0.48
+63.1%
$-1.30
+36.0%
$-2.03
Shares (Diluted)
42.5M
+41.1%
30.1M
-25.7%
40.6M
+109.1%
19.4M
+46.7%
13.2M
Immunic (IMUX) โ€” Financials